Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/13993003.00081-2017
Abstract: Tuberculosis (TB) patients with multidrug-resistant (resistance to isoniazid and rifampicin) (MDR-TB) or rifampicin-resistant strains (MDR/RR-TB) do not respond to the standardised first-line TB regimen which is highly effective in other TB patients, requiring much longer… read more here.
Keywords: shorter treatment; novel shorter; tuberculosis; multidrug resistant ... See more keywords